Johnson & Johnson shows positive results in lung cancer study
![](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/14779801/dxzmxu/ALTERNATES/schema-16_9/Johnson%2520&%2520Johnson.jpg)
Genmab’s US partner Johnson & Johnson has successfully completed a phase III study with the drug, Rybrevant, for the treatment of metastatic lung cancer.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.